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Molecular self-assembly is a multi-disciplinary ﬁeld of research, with potential chemical and biological
applications. One of the main driving forces of self-assembly is molecular amphiphilicity, which can drive
formation of complex and stable nanostructures. Self-assembling peptide and peptide conjugates
have attracted great attention due to their biocompatibility, biodegradability and biofunctionality.
Understanding assembly enables the better design of peptide amphiphiles which may form useful and
functional nanostructures. This review covers self-assembly of amphiphilic peptides and peptide mimetic
materials, as well as their potential applications.
Peptide self-assembly
Self-assembly is defined as the ability of a molecule, without
guidance of external factors, to associate through non-covalent
interactions to form highly ordered 3-dimensional structures.1
This occurs through a bottom-up approach. Most self-assem-
bling molecules have both hydrophobic and hydrophilic com-
ponents, and are termed amphiphilic.1 Lipids are perhaps the
simplest molecule displaying amphiphilicity, with a hydro-
philic head group, and a hydrophobic tail group. Peptides and
proteins are more complex in their amphiphilicity. This is
largely due to folding, giving rise to ‘faces’, diﬀerent folded
surfaces which are exposed to diﬀerent environments. For
example, a β-sheet peptide may contain alternating hydrophilic
and hydrophobic residues, resulting in the side chains being
exposed on opposite sides of the sheet.2
Self-assembly is commonly found in nature. A natural
example of a self-assembled structure is the phospholipid
bilayer, which is the basis of cell membranes, vesicles and
organelle membranes in cells and bacteria.3 Another example
is microtubules, which are cytoskeletal components of eukary-
otic and some prokaryotic cells. Microtubules are a main com-
ponent of the mitotic spindle in cell division which contracts
to pull apart chromosomes in eukaryotes, and in prokaryotes
make up the internal structure of cilia and flagella in bacteria
enabling movement.4,5 Other examples include protein folding
in enzymes, DNA double helix formation and the formation of
the virus protein capsid around a nucleic acid core.6
In aqueous environments, self-assembly is driven by non-
covalent forces to form ordered structures ranging from the
manometer to micron size.7 These non-covalent interactions
include van der Waals forces, hydrophobic interactions,
electrostatic interactions, hydrogen bonding and π–π stacking
(aromatic) interactions.1,8 These interactions are weak, for
example the backbone hydrogen bonding in peptides having
an estimated energy of 4.2 kcal mol−1 in a gaseous environ-
ment, which decreases in solution.9 However, these inter-
actions are enough to stabilise these robust structures. In turn,
this means self-assembly can be influenced by temperature,
pH and concentration. Some of the most common structures
(Fig. 1) include micelles, vesicles and fibrillar structures (nano-
tubes, fibres).10
Micelles can be spherical, worm-like or disk-shaped assem-
blies and form spontaneously above a critical micelle aggrega-
tion concentration and temperature.11,12 Vesicles are spherical,
lamellar structures which are hollow, surrounding an aqueous
core. Hydrophilic layers are exposed to the inner and outer
aqueous environments, whilst hydrophobic residues pack
together between hydrophilic interfaces.13
Hydrogen bonding between the backbone of peptide chains
is an important factor in peptide self-assembly, as it drives
longitudinal packing of peptide monomers into β-sheets. Inter
β-sheet interactions among side chains of peptide molecules
regulate the lateral packing of the β-sheet at a slow rate com-
pared to the fast growth in the hydrogen-bonding direction.
Packing of β-sheets, which are naturally twisted due to chiral-
ity, favours reduced twisting. Lateral interactions overcome the
energy penalty due to untwisting.2 Thus, the final assembled
morphologies are the result of these confinements, inter-
actions and/or their interplay.2
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Peptide amphiphiles (PAs)
A peptide amphiphile (PA) (Fig. 2) is defined by having a
hydrophobic tail group, usually an alkyl chain, which leads to
hydrophobic interactions, a peptide sequence that is able to
form intermolecular hydrogen bonds, which determines the
interfacial curvature of self-assembly, a section of charged
amino acids to promote solubility and a functional peptide
epitope that has bioactivity.14 The amphiphilicity of the mole-
cule drives self-assembly, which draws the functional peptide
group to the surface of the structure. Self-assembly occurs
above a critical aggregation concentration (CAC). This can be
measured using fluorescence methods, light scattering or
proton NMR solubility measurements.1
Self-assembly of peptide amphiphiles has been widely
studied due to their potential to assemble into a large range of
novel nanostructures which are of interest commercially and
biomedically. These structures can be monolayer-based (for
example micelles), or bilayer-based (for example vesicles).15
The self-assembled structure of a peptide can largely be con-
trolled by amino acid sequence, length of sequence and lipida-
tion. Thus they are a malleable tool in order to make novel bio-
materials. Some of their potential uses include drug delivery,
tissue engineering and antimicrobial agents.1
The self-assembly of PAs and peptide-based molecules can
be tuned by control of pH, temperature, concentration and
other factors, as discussed in other reviews.1,8,16–18 This gives
excellent scope to create biomaterials responsive to many or
multiple environmental cues.
Diﬀerent classes of peptide-based molecules which will be
reviewed include here peptides with polar and nonpolar resi-
dues giving rise to hydrophobic and hydrophilic properties,
named surfactant-like peptides (SLPs), and hydrophilic
peptides attached to a hydrophobic lipid alkyl chains,
named PAs.
Amphiphilic lipopeptides
Self-assembling amphiphilic lipopeptides are a class of mole-
cules defined as having a one or more lipid chains attached to
a peptide head group. The self-assembly of this class is
thought to depend upon the hydrophile/lipophile balance
(HLB).19 They oﬀer advantages compared to peptides, as they
oﬀer increased amphiphilicity and are compatible with the
phospholipid bilayer (which makes up cell membranes),
Fig. 1 Possible self-assembled structures of peptide amphiphiles. Amphiphilic peptides may assemble into secondary structure through inter and
intra molecular interactions (e.g. electrostatic interactions and hydrogen bonding), and continue to aggregate into larger self-assembled structures.8
Fig. 2 Typical structure of a peptide amphiphile. The four domains that incorporated into the Stupp group’s design of bioactive β-sheet forming PA
assemblies.14
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enabling them to deliver actives into cells via endocytosis.
Additionally, self-assembly of lipopeptides facilitates the pres-
entation of peptide functionalities at high density at the
surface of nanostructures (micelles, vesicles or fibrils).
The length of lipid chain on the self-assembly of PAs has
been considered in several studies which are discussed in a
recent paper.20 Essentially, studies so far21 indicate that a
minimal chain length (typically C6–C10) is required for the con-
jugate to exhibit self-assembly. Shorter chains attached to
hydrophilic peptides lead to PAs that are just “too soluble”. Of
course the sequence and length of the peptide will also influ-
ence amphiphilicity of the PA conjugate as well as many other
factors such as electrostatic interactions, hydrogen bonding,
van der Waals interactions π–π stacking interactions etc. There
are no universal rules for this, however PAs with less than a
couple of charged residues will not be water soluble and at
least 2 or more heptad repeats is required to observe α-helix
formation.
Many naturally expressed bioactive lipopeptides contain
one lipid chain (C14–C18) with a cyclic head group. Cyclisation
is thought to have evolved to reduce proteolysis, thus enhan-
cing in vivo stability. However, these conformational peptide
constraints may be relevant to bioactivity. In bacteria, many
naturally occurring amphiphilic lipopeptides are produced as
part of a host defence response against other organisms.22
This has many interesting uses clinically. An example is dapto-
mycin, produced by the Gram positive bacterium, Streptomyces
roseoporous, which is used to treat MRSA and self-assembles
into micelle structures.23,24
Synthetic amphiphilic lipopeptides tend to be based on a
bio-derived sequence, often containing a linear peptide head
group with 1–3 (usually palmitoyl) lipid chains attached. An
example is Toll-like receptor agonists. Toll-like receptors
(TLRs) are transmembrane proteins which are part of the
innate immune response, making them an important thera-
peutic target. Agonists of TLRs were designed based on the
Pam3Cys peptide (where Pam denotes a C16 chain). This syn-
thetic peptide has been shown to stimulate cytotoxic T lym-
phocyte (CTL) responses against cells infected with influenza
virus.25 Another related lipopeptide to this is Pam3CysSer2
which has been shown to stimulate antibodies against foot
and mouth disease.26 Pam1CKS4 and Pam2CSK4 (Fig. 3)
have recently been shown to self-assemble into spherical
micelles in contrast to Pam3CSK4 which forms bilayer-based
structures.27
Surfactant-like peptides
Surfactant-like peptides (SLPs) are peptides containing
sequences of both hydrophobic and hydrophilic amino acids,
which self-assemble in a similar way to PAs. Popular examples
of this include A6D and V6D.
28 Alanine-containing SLPs have
found to self-assemble into more stable structures due to
stronger hydrophobic interactions, in contrast to other hydro-
phobic amino acid residues.
SLPs tend to feature 1–2 charged amino acids that form a
hydrophilic head group, and 4 or more consecutively hydro-
phobic amino acids.29 Early studies of self-assembly of this
group showed that in water they undergo self-assembly to from
bilayered nanovesicles and nanotubes, with an average dia-
meter of 30–50 nm.30 Nanotubes are thought to form from
bilayers of peptide molecules, which resemble sheets. These
sheets then roll up to form tubes, which have a defined dia-
meter, and continue to grow from the edges. More recently,
SLPs have been prepared that form micelles through packing
of hydrophobic tails, or nanofibers. Two variants of A6K were
shown to have diﬀerences in assembly due to deprotection of
Fig. 3 Structure of Toll-like receptor agonists (a) Pam1CSK4, (b) Pam2CSK4 and (c) Pam3CSK4.
27
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the C-terminis or change in the pH of the solution. Peptide
A6K with the sequence Ac-AAAAAAK-CONH2 was observed to
form nanofibers at low pH and pH 6, and amorphous aggregates
at high pH. When the protecting NH2 group at the C-terminus
was removed, leaving the sequence Ac-AAAAAAK-COOH (named
A6K±), it was shown to form short nanofibers at low pH, longer
fibres at pH 5, and nanospheres at high pH.31 This was
studied using atomic force microscopy, dynamic light scatter-
ing and transition electron microscopy (TEM). The diﬀerence
at high pH was thought to be due to the ability of the carboxyl
group in the second variant to disassociate. A6K has also been
shown to form single layer nanotubes using cryo-TEM and
SAXS (small angle-X-ray scattering), and NMR (Fig. 4).32,33
SLPs have promising potential to be used in the study of
membrane proteins because they can form layered structures
like lipids. Membrane protein purification is a complex
process due to the size and interactions membrane proteins
have with the lipid bilayer. Surfactant-like peptides could be
used to bind the hydrophobic section of the membrane
protein and sequester it from water, thus preventing denatura-
tion. For example, surfactant-like peptides have been shown to
enhance the stability of bovine rhodopsin, a G-protein coupled
receptor.30
Applications
Peptide amphiphiles have many applications. Some appli-
cations, including biomineralization,34–36 membrane stability
enhancement37–40 and antibody production41,42 are not
covered here but are described in detail elsewhere.17,43
Tissue scaﬀolds
Tissue scaﬀolds are engineered materials that mimic the extra-
cellular matrix (ECM), and are designed to allow cell attach-
ment/migration, enable diﬀusion of desired molecules, exert
mechanical and biological influences to modify the behaviour
of the cells, or to deliver and retain cells and biochemical
factors. Peptide amphiphiles have been shown to have many
potential applications in this field. As this has been extensively
reviewed elsewhere,44,45 it is not discussed in detail again here.
Furthermore, excellent overviews of the material requirements,
including the incorporation of peptide motifs, in the develop-
ment of biomaterials for tissue engineering applications are
also available.46–51 Peptide motifs that have an important role
in such biomaterials include cell adhesion sequences.
One of the most commonly studied cell adhesion motifs is
the integrin recognition motif RGDS from fibronectin.52–56
Tirrell’s group attached RGD units either through amino or
carboxyl units to dialky lipid chains (Fig. 5). They also pre-
pared a conjugate which contained loops connected by linkers
to dialkyl chains on both sides.57 It was found that lipid chain
attachment to the RGD peptides eﬀected melanoma spreading.
The amino conjugated PA was found to hinder spreading,
whilst the looped PA was found to promoyr concentration-
dependent spreading, and indiscriminate spreading was
observed for the carboxyl coupled PA. Further studies based on
liposomes revealed that spontaneous metastasis could be
inhibited by RGD based PAs.58
Fig. 4 Structure of A6K self-assemblies in water. (a) TEM image of A6K nanotubes in water, scale bar = 200 µM (b) schematic diagram of three per-
spectives of the nanotubes formed by A6K as shown through TEM, NMR and FTIR.
33
Fig. 5 Structure of RGD based peptides. (A) Amino-coupled RGD,
(C18)2–Glu–C2–RGD, (B) carboxyl-coupled RGD, RGD–C2–Glu–(C18)2,
and (C) looped RGD, (C18)2–Glu–C2–RGD–C2–Glu–(C18)2.
57
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PAs have also been shown to have promise in regenerative
medicine. PA nanofibril gels containing peptides incorporating
a cell adhesion motif, IKVAV have been observed to encapsulate
cells and rapidly diﬀerentiate them into neurones.59 This same
PA has been shown to eﬀective in a mouse model for treating
spinal cord injury, the self-assembling nanofibers inhibiting
glial scar formation and promotion of axon elongation. Other
PAs have been shown to be eﬀective in cartilage regeneration
using bone marrow derived stem and progenitor cells.60
The lipopeptide amphiphile Matrixyl (C16-KTTKS), is a com-
ponent of an antiwrinkle cream which has shown to stimulate
collagen production in fibroblasts,61 undergoes self-assembly
in aqueous solution.17 At present, it is not known whether the
self-assembly directly influences its bioactivity and nor is it
established whether the prior studies showing increased col-
lagen production in fibroblasts at concentrations where the PA
begins to aggregate61 are relevant in vivo. The skin contains a
significant barrier of keratin and lipid membranes in the
stratum corneum and the transport of the PA across this
barrier has not been carefully examined, although some strip-
ping studies of the stratum corneum with radiolabelled
peptide have been performed to probe penetration of PAs.62
The discovery that C16-KTTKS self-assembles into highly
extended nanotape structures63 may be relevant to one aspect
of anti-wrinkle treatment in that when the applied skincare
cream is applied, dried micron scale fibrillar structures could
act as filler. The PA C16-KTTKS has been shown to have β-sheet
secondary structure and form bilayer-based nanotapes32 which
are stable between the pH range of 3–7 at room temperature.
However, pH reduction/increase64 or increased temperature65
favours random coil secondary structure, and spherical micelle
self-assembly.
Delivery and cell internalization
Transportation of hydrophobic drugs and other active mole-
cules into cells is an important and ongoing biomedical chal-
lenge. PA-based nanocarrier systems have shown potential and
are usually designed based upon natural sequences. An
example is a PA comprising of a tandem dimer, containing
binding sites for LDL (low-density lipoprotein) receptor and
cell-surface heparin sulphate proteoglycans. Internalisation of
the PA into brain capillary endothelial cells was imaged using
fluorescent techniques, showing potential drug transport
applications.66 Another example of a delivery system is a PA
containing cell adhesive MMP-2 sensitive peptide domain,
which was shown to form fibrillar hydrogels. This PA
can delivery anti-cancer agent cisplatin through enzymatic
degradation.67
Cationic PAs have also been shown to be useful in gene
therapy. The PAs H5R10 and H10R10 were conjugated to chole-
sterol.68 They were shown to assemble into cationic micelles,
which lead to increased localization of charge and increased
DNA binding. H10R10 was shown to stimulate higher gene
expression, probed through use of a reporter gene in HEK293
and Hep62 cells.68 Moreover, A12H5K10 and A12H5K15 were also
investigated.69 Through the same reporter assay, these PAs
were shown to have improved gene expression compared to
non-amphiphilic control peptide, and a more favourable cyto-
toxicity profile compared to polyethyleneimine (PEI), a com-
monly used synthetic DNA-condensing polymer. Simultaneous
delivery of genes (either p53 tumour suppressor or luciferase
reporter gene) and doxorubicin was examined using
Ac-(AF)6H5K15-NH2.
70 This PA self-assembled into micelles
with the ability to encapsulated condensed DNA and doxo-
rubicin, with delivery eﬃciency and in vitro expression exam-
ined in HePG2 cells.
It has also been possible to use PAs to study endocytosis.
One such PA, based on p53 tumour suppressor, comprised this
pro-apoptotic peptide attached to C16 lipid chain (Fig. 6).
Internalization was investigated using fluorescent methods. This
PA was shown to self-assemble into rod-shaped micelles. FRET
(fluorescence resonance energy transfer) showed internalization
of monomers into SJSA-1 human osteosarcoma cells as opposed
to micelles, and uptake was enhanced by lipidation.71
Antimicrobial peptides
Short cationic peptides can exhibit antimicrobial properties.
Lipidation is thought to enhance antimicrobial properties of
cationic peptides.72 Lipidation causes changes in secondary
structure as the peptide interacts with the membranes. The
exact mechanism by which these peptides act upon bacteria
and fungi is unknown. Reports on di- and tri-lysine PAs
showed that antimicrobial activity against Gram-positive and
Gram-negative bacterial occurred through leakage, caused by
cell membrane disruption.73
Surfactins, iturins and lichenysin are lipopeptides with
molecular structures shown in Fig. 7, which have antifungal
properties.73 Surfactin, produced by B. subtilis, has the ability
to reduce the surface tension of water to 27 mN m−1 at concen-
trations as low as 20 µM. It was found through neutron scatter-
ing to self-assemble into spherical micelles in bulk aqueous
solution, and to adopt a more globular conformation at the
interface (for example air/water).19 The self-assembly of surfac-
tin and two other lipopeptides produced by B. subtilis, plipa-
statin and mycosubtilin were also examined using biophysical
techniques. Small-angle X-ray scattering (SAXS) and Cryo-TEM
confirmed that surfactin and plipastatin self-assembled into
spherical micelles, whereas mycosubtilin formed nanotapes
based on bilayer stacking.74 It remains an open question as to
whether the self-assembly influences bioactivity, changing the
Fig. 6 Schematic diagram of PA based on p53 tumour suppressor
protein internalisation into SJSA-1 human osteosarcoma cell line.71
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interaction of the peptide with receptor directly or via shifts in
the molecule-aggregate equilibrium.
Arginine rich SLPs have been shown to have some anti-
microbial properties. An example is the TAT (YGRKKRRQRRR)
peptide from HIV retrovirus which has been shown to have
antimicrobial properties, and contains 6 arginine and 2 lysine
residues. It was found that substitution of any basic residues
lead to a decrease in antimicrobial activity. TAT peptide is
commonly used to transport peptides and proteins across cell
membranes.75 Liposomes decorated with TAT peptide have
also been investigated with potential as a drug delivery vehicle
for the anticancer drug paclitaxel.76 Conjugation of TAT to
polyarginine and cholesterol shows improvements in mem-
brane translocation, as well as in antimicrobial strength. This
PA assembles into micelles, and has shown to be eﬀective in
rabbit and mouse models against S. aureus.77 PAs have also
demonstrated promise in sepsis treatment. Sepsis (blood poi-
soning) is induced by bacterial endotoxins, namely lipopoly-
sacharrides. A PA was designed based on natural immune
response antibodies against sepsis. It was found that increased
eﬀective neutralisation of lipopolysacharrides by the PAs corre-
lated with increased lipid chain length. Interestingly, two
other designed PAs with lipopolysacharride binding
sequences, attached to C16 alkyl lipid chain were shown to self-
assemble into fibrils.78
Peptide hydrogels
A hydrogel is defined as a water swollen, cross-linked or
entangled polymeric network. Hydrogels may form through
non-covalent processes such as the formation of a sample-
spanning fibrillar network or they may be created through
covalent cross-linking within pre-existing or produced network
structures. Some hydrogels are able to absorb large amounts
of water and they may also be designed to have mechanical
properties similar to natural tissue. Hydrogel formation can be
very dependent upon temperature, pH, concentration of
polymer or salts.79
Hydrogels can be made of natural or synthetic materials,
and can be prepared through use of homopolymers, copoly-
mers or multi-polymer networks. Homopolymeric hydrogels
contain one polymer, copolymer networks contain two or
more polymers interacting with each other to form the fibrillar
network, and co-networks contain two independent fibril
forming monomers. They can be non-crystalline, semi-crystal-
line or crystalline.79 Formation can occur through covalent
interactions between monomers, or through electrostatic inter-
actions or hydrogen bonding, van der Waals or ionic
interactions.
Peptides and peptide conjugates have the ability to form
hydrogels. Hydrogelation can result from non-covalent self-
assembly processes under appropriate conditions.80 For
example, for fibre-based hydrogels, self-assembly might occur
involving the formation of nanofibers from β-sheet peptides.
These fibres may then elongate in three dimensions, leading
to increased fibre thickness and length, ultimately leading to
fibrillar network formation. These complex networks of pep-
tides may then entrap water, thus providing a self-supporting
hydrogel. Peptides and peptide conjugates with other second-
ary structures, for example α-helical, have also been shown to
be able to form hydrogels.81
For biomedical applications, it is essential that the gels are
biocompatible. Synthetic hydrogels may induce an immune
inflammatory response, which could have potential cyto-
toxicity. For example, although PEG is often considered an
“inert” polymer, high molar mass PEG is not degraded in vivo
and can cause toxicity, as can high doses of PEG polymers of
low molar mass.82–85 Immunogenic response to PEG has been
reported.84,86 Furthermore, synthetic PEG may contain impuri-
ties or unreacted monomer which is highly toxic. PEG-peptide
and PEG-protein hydrogels and alternatives based on other
synthetic polymers are the subject of recent reviews.84,87,88
Natural hydrogel polymers, for example peptide functionalised
polymer hydrogels,89–95 can be designed to be highly biocom-
patible. A number of other physical parameters, for example
degradation and performance (for example cell adhesion)
must also be considered. The mechanism by which the hydro-
gel forms is important. Gels formed by ionic cross-linking may
be prematurely degraded in vivo due to electrostatic inter-
actions in body fluids, making covalent cross-linking preferred
in this way. Some examples of other naturally occurring poly-
mers include fibrin, collagen and gelatin25 and hyaluronate.
The most popular FDA approved synthetic polymers are poly
(acrylic acid) derivatives and poly(ethylene oxide) (PEO).96
Hydrogels have also been shown to have applications in cell
culturing. Peptide hydrogels for cell culturing must mimic the
extracellular matrix and incorporate peptide adhesion motifs.
RGD, from is one of the most widely used peptide sequences
for this purpose. In one example, an Fmoc-RGD peptide was
shown to form β-sheet secondary structure, and self-assemble
into amyloid fibrils. The hydrogel formed by Fmoc-RGD was
shown to be capable of sustaining cells and to support fibro-
blasts compared to a control scrambled sequence.97 Other
applications for peptide and peptide conjugate hydrogels
include biosensors,98 regenerative medicine and tissue
engineering,99–109 and slow release drug delivery systems.110–115
Fig. 7 Chemical structure of three bacterially derived lipopeptides.
(A) Surfactin, (b) plipastatin and (c) mycosubtilin.74
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Peptide-mimetic polymers and
self-assembly
The abundant uses of peptides biomedically, biologically and
commercially has led to significant interest in polymers
designed to have similar characteristics. One class of peptide-
mimetic materials are peptoids or N-substituted glycines
(Fig. 8). They are structural isomers of peptides, with the side
chain attached to the amide nitrogen as opposed to the
α-carbon,116 resulting in novel morphologies. The positioning
of the side chain interrupts intra- and inter-back bone hydro-
gen bonding which holds together peptide secondary struc-
ture. Helices, ribbons and sheets may be formed, through
careful molecular design including selection of the sidechains.
Their nature also makes them resistant to proteolysis and bio-
degradation, making them suitable for some applications
including long-term biointerfaces and biomaterials, as well as
antimicrobial peptidomimics.116
There is a defined method for synthesising sequence-
specific peptoids, and bioactive sequences can be developed
through use of combinatorial library searches.116 One example
of a clinically used peptide is poly(N-methyl glycine, polysarco-
sine) which is prescribed as a non-immunogenic. Biomedical
studies also show promise, including a study cell viability assays
showing that they can be tolerated at significant concentrations
before they are cytotoxic. This makes them an interesting
material for drug delivery. Other studies have included develop-
ment of protein-mimetics and membrane spanning helices.116
Self-assembly of peptoids is currently attracting much atten-
tion. They have been shown to assemble into nanosheets
dependent on sequence (Fig. 9), with a mixture of hydrophobic
and ionic monomer units, which may extend to micron size
laterally.117–119 Hollow nanotubes assemblies have been
observed in water, without a central hydrophobic core, chiral-
ity, electrostatic interactions, hydrogen bond network or
π-stacking.120 The nanotube is thought to be stabilised by van
der Waals interactions between side-chains as a pose to hydro-
gen bonds which stabilise peptide structure.120 Worm-like vesi-
cles and micelles structures have been observed.121 Lipidation
of peptoids, inspired by lipopeptide assembly has been shown
to enhance designability of assembly. Ultra-small spherical
micelles of 5 nm diameter have been designed based on this
principle, with subtle variations in size due to sequence
changes.122
Hybrid oligo(peptoid-peptides) are a combination of pep-
tides and peptoids with potential biomedical applications and
interesting self-assembly behaviour. Few studies have been
done on this type of molecule, however there are a few
examples such as, cyclosporin123 isolated from Hypocladium
inflatum gams fungus, which is a naturally occurring and clini-
cally used immunosuppressant.124 Self-assembly of this class
of conjugate has not been explored extensively. It has been
shown that these nanosheets may curl to form nanotubes or
microtubes.125 Core–shell micelle structures have recently
been observed from synthetic oligo(peptoid-peptide) hybrid
molecules.126
Conclusions
Self-assembly is a vital process in nature, driving aggregation
in a manner that depends on the conditions (concentration,
pH, temperature, presence of salts etc.). Peptide amphiphiles
and designed peptide-mimetic molecules are able to self-assem-
ble into complex stable nanostructures. The examples presented
above include peptides and conjugates with bioactive functions
which can be exploited, for clinical use, commercial use, or to
further understand the self-assembly process.
Surfactant-like peptides are simple peptide systems which
can potentially be produced inexpensively and at large scale
(by genetic engineering for instance) for applications such as
antimicrobials or membrane protein support. Their self-
assembly behaviour is remarkably rich and is the subject of
Fig. 8 Structure of peptoid polymer. Peptoids are structural isomers of
peptides, with the R group attached to the amide group as opposed to
the α-carbon.
Fig. 9 The structure of nanosheets formed from oppositely charged
peptoid polymers. (a) Chemical structure of a negatively charged peri-
odic amphiphilic peptoid (Nce–Npe)18. (b) Chemical structure of a posi-
tively charged periodic amphiphilic peptoid (Nae–Npe)18. (c) Molecular
model of the sheets assembled from (Nae–Npe)18 and (Nce–Npe)18. The
modelled conformation shows that hydrophobic groups face each other
in the interior of the sheet and oppositely charged hydrophilic groups
are alternating and surface-expose. Atom colours: carbon, yellow; nitro-
gen, blue; oxygen, red.119 Nce denotes N-2(carboxyethyl)glycine, Npe
denotes N-2(phenylethyl)glycine and Nae denotes N-2(aminoethyl)
glycine.
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ongoing investigation, exploring the role of charge, sequences
and the nature of the constituent amino acids. There is also
great scope to prepare novel peptide-mimetics based on pep-
toids and their conjugates for example. These will have new
applications and are likely to show unanticipated self-assembly
behaviour. This will be a rich field for future research.
New antimicrobial peptides are being discovered in nature,
a process likely to continue given the need to create new
agents to overcome antimicrobial resistant infections. Newly
discovered natural antimicrobial peptides and their derivatives
can be complemented with novel designed peptides.
Cyclisation is an important tool to stabilize these molecules
in vivo, for applications as antimicrobials and for other thera-
peutic peptide-based compounds. The influence of cyclisation
on self-assembly is an interesting avenue for further research.
Certainly one can expect the packing of the molecules to be
influenced due to the large steric bulk of cyclic peptides which
can form the “headgroup” in peptide amphiphiles.
A key question that remains unresolved is whether there is
a relationship between bioactivity and self-assembly of peptide
amphiphiles. The reason the answer remains elusive is due to
the complexity of the question. It is very diﬃcult to decouple
the eﬀect of self-assembly from the concentration eﬀect on
bioactivity. One method suggested would be to cross-link self-
assembled structures, trapping them in a specific thermo-
dynamic state.19 However, this may interfere with the self-
assembled structure and potentially impact the resultant
recorded bioactivity. It is also not straightforward to observe
substrate and molecule/aggregate interactions without perturb-
ing the molecule-aggregate equilibrium. It is likely that there
will be some cases where self-assembled structures themselves
impart bioactivity, and others where there is no direct relation-
ship between self-assembly and bioactivity, particularly in the
circumstances where bioactivity is observed below the critical
aggregation concentration. It is possible that there may be an
indirect relationship, where amphiphilicity leads to greater
bioactivity, through for example increased membrane compat-
ibility, this amphiphilicity, in turn, leading to self-assembly at
high concentrations.
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